Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

Jarrod Longcor, Kate Oliver, BS

Blood (2019) 134 (Supplement_1): 1864.

https://doi.org/10.1182/blood-2019-131806

Published: 2019

Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2019) 134 (Supplement_1): 2574.

https://doi.org/10.1182/blood-2019-123287

Published: 2019

Journal Articles

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Bae P Chu, MPH, Neeta Pandit-Taskar, MD, Boglarka Gyurkocza, MD, Qing Liang, PhD, Daniel Miodownik, MPH, Vijay Reddy, MD PhD, Mark S. Berger, MD, Lawrence T. Dauer, PhD

Blood (2019) 134 (Supplement_1): 5839.

https://doi.org/10.1182/blood-2019-131230

Published: 2019

Journal Articles

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Dale Ludwig, PhD BS, Ruth Bryan, Wojciech Dawicki, PhD, Eileen M Geoghegan, Qing Liang, PhD, Sandesh Seth, MS, MBA, Mamata Gokhale, Mark S. Berger, MD, Vijay Reddy, MD PhD, Ravendra Garg, Kevin Allen, PhD, Ekaterina Dadachova

Blood (2019) 134 (Supplement_1): 5601.

https://doi.org/10.1182/blood-2019-128678

Published: 2019

Journal Articles

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Blood (2018) 132 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2018-99-110555

Published: 2018

Journal Articles

Retrospective Cohort Study Assessing the Prognostic Value of Baseline Necrosis on PET-CT in Hodgkin Lymphoma

Nuno Borges, MBBS, Isobel Chen, MBChB, Luke Winn, FRCPath, Wendy Osborne, MBBS, George Petrides, FRCR

Blood (2018) 132 (Supplement 1): 5359.

https://doi.org/10.1182/blood-2018-99-111904

Published: 2018

Journal Articles

Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Amal Saidi, PhD, Astri Maaland, Julien Torgue, PhD, Helen Heyerdahl, PhD, Jostein Dahle, PhD

Blood (2018) 132 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2018-99-110297

Published: 2018

Journal Articles

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2018) 132 (Supplement 1): 1371.

https://doi.org/10.1182/blood-2018-99-110200

Published: 2018

Journal Articles

Personalizing Amyloidosis Therapy with Real Time PET Imaging of Fibril-Reactive Monoclonal Antibody Cael-101

Jing Fu, PhD, Alan Solomon, MD, Patrick Carberry, PhD, John Castrillon, Jongho Kim, MD PhD, Suzanne Lentzsch, MD PhD, Akiva Mintz, MD PhD

Blood (2018) 132 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2018-99-118177

Published: 2018

Journal Articles

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Blood (2018) 131 (7): 741–745.

https://doi.org/10.1182/blood-2017-09-807263

Published: 2018

Includes: Multimedia, Supplemental data

Journal Articles

Targeting Burkitt's Lymphoma Using Novel, Discrete Carbon Nanotubes

Carolyne Falank, PhD, Aaron Tassett, BS, Sophie Harris, BA, Mariah Farrell, BS, Paul Everill, PhD, Michaela Reagan, PhD

Blood (2017) 130 (Supplement 1): 1476.

https://doi.org/10.1182/blood.V130.Suppl_1.1476.1476

Published: 2017

Journal Articles

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Blood (2017) 130 (Supplement 1): 2769.

https://doi.org/10.1182/blood.V130.Suppl_1.2769.2769

Published: 2017

Journal Articles

Copper-64-Labeled Daratumumab As a PET Imaging Tracer for Multiple Myeloma: Potential Use for Minimal Residual Disease Detection

Enrico Caserta, PhD, Junie Chea, Megan Minnix, Domenico Viola, BS, Steven Vonderfecht, Jonathan J Keats, PhD, James F Sanchez, David Colcher, John E. Shively, Amrita Krishnan, MD, Flavia Pichiorri, PhD

Blood (2017) 130 (Supplement 1): 3083.

https://doi.org/10.1182/blood.V130.Suppl_1.3083.3083

Published: 2017

Journal Articles

Preliminary Data Show Heterogenous Patterns of 18 f-FDG PET/CT When Assessing the Inflammatory Component of Primary or Secondary Myelofibrosis

Mario Ojeda-Uribe, Christophe Schohn, MD, Olivier Morel, MD, Nathalie Mac Dougall, MD, Xavier Malezieux, MD, Atteka Chabanse, PharmD, Andrien Norosoa, MD, Laurent Mauvieux, MD PhD, Hatem Boulahdour, MD PhD, Edmond Rust, MD

Blood (2017) 130 (Supplement 1): 5280.

https://doi.org/10.1182/blood.V130.Suppl_1.5280.5280

Published: 2017

Journal Articles

Combination of 177 lutetium-Satetraxetan-Lilotomab and Rituximab Results in Improved Therapeutic Effect in Preclinical Models of Non-Hodgkin Lymphoma

Ada H.V. Repetto-Llamazares, PhD, Roy Hartvig Larsen, PhD, Adam O'Shea, Jostein Dahle

Blood (2016) 128 (22): 4189.

https://doi.org/10.1182/blood.V128.22.4189.4189

Published: 2016

Journal Articles

The Health Related Quality of Life Is Maintained Following Treatment of Indolent Non-Hodgkin's Lymphoma Patients with the Novel Effective Antibody Radionuclide Conjugate 177 lu-Satetraxetan-Lilotomab

Arne Kolstad, MD PhD, Matthew Beasley, Michael Bayne, Ingemar Lagerlöf, Noelle O'Rourke, Jostein Dahle, Laurie Baylor Curtis, Åse Østengen, Simon Turner, Roy Hartvig Larsen, Harald Holte

Blood (2016) 128 (22): 5339.

https://doi.org/10.1182/blood.V128.22.5339.5339

Published: 2016

Journal Articles

Evaluation of a Rapid and Automated Heparin-Induced Thrombocytopenia Immunoassay

Majed A. Refaai, MD, Grace Conley, John L. Francis, Thomas L. Ortel, MD, PhD

Blood (2016) 128 (22): 2546.

https://doi.org/10.1182/blood.V128.22.2546.2546

Published: 2016

Journal Articles

Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin ® ) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Bjørg Bolstad, MSc, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Jostein Dahle, PhD, Nils Bolstad, MD, Roy Hartvig Larsen, PhD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD

Blood (2015) 126 (23): 5118.

https://doi.org/10.1182/blood.V126.23.5118.5118

Published: 2015

Journal Articles

BARs ( B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms

Michael Pfreundschuh, MD, Lorenz Thurner, MD, Stefan Barth, Prof.Dr., Diana Pickert, Natalie Fadle, Maria Kemele, Evi Regitz, Frank Neumann, PhD, Thomas Nachreiner, Dr., Klaus-Dieter Preuss, PhD

Blood (2015) 126 (23): 3995.

https://doi.org/10.1182/blood.V126.23.3995.3995

Published: 2015

Journal Articles

Treatment with 177 lu-HH1 Increases CD20 Expression in Non-Hodgkin Lymphoma Cells in Vitro and In Vivo

Ada H.V. Repetto-Llamazares, PhD, Roy Hartvig Larsen, PhD, Landsverk Kirsti, PhD, Trond Stokke, PhD, Bergthora Eiriksdottir, PhD, Roman Generalov, MSc, Jostein Dahle, PhD

Blood (2015) 126 (23): 3245.

https://doi.org/10.1182/blood.V126.23.3245.3245

Published: 2015

NARROW

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Retrospective Cohort Study Assessing the Prognostic Value of Baseline Necrosis on PET-CT in Hodgkin Lymphoma

Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Personalizing Amyloidosis Therapy with Real Time PET Imaging of Fibril-Reactive Monoclonal Antibody Cael-101

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Targeting Burkitt's Lymphoma Using Novel, Discrete Carbon Nanotubes

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Copper-64-Labeled Daratumumab As a PET Imaging Tracer for Multiple Myeloma: Potential Use for Minimal Residual Disease Detection

Preliminary Data Show Heterogenous Patterns of 18 f-FDG PET/CT When Assessing the Inflammatory Component of Primary or Secondary Myelofibrosis

Combination of 177 lutetium-Satetraxetan-Lilotomab and Rituximab Results in Improved Therapeutic Effect in Preclinical Models of Non-Hodgkin Lymphoma

The Health Related Quality of Life Is Maintained Following Treatment of Indolent Non-Hodgkin's Lymphoma Patients with the Novel Effective Antibody Radionuclide Conjugate 177 lu-Satetraxetan-Lilotomab

Evaluation of a Rapid and Automated Heparin-Induced Thrombocytopenia Immunoassay

Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin ® ) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

BARs ( B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms

Treatment with 177 lu-HH1 Increases CD20 Expression in Non-Hodgkin Lymphoma Cells in Vitro and In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only